CD93-28z CAR T cells

CD93-28z CAR T cells are an experimental, preclinical second-generation chimeric antigen receptor (CAR) T-cell therapy targeting CD93 (also known as C1qR1), a cell surface glycoprotein highly expressed on acute myeloid leukemia (AML) blasts and leukemia stem cells (LSCs). The CAR construct utilizes a humanized single-chain variable fragment (scFv) derived from the F11 antibody clone, fused to a CD28 costimulatory domain and a CD3-zeta (ζ) activation domain. Developed by researchers at Stanford University, these CAR T cells have demonstrated potent anti-leukemic efficacy in vitro and in patient-derived xenograft (PDX) models of AML. However, investigations have revealed that CD93 is also expressed on healthy endothelial cells, leading to on-target, off-tumor toxicity in preclinical models, which suggests a need for combinatorial targeting or logic-gated CAR designs to improve safety for clinical application.

Other names

CD93-CD28-CD3z CAR T cellsCD-93-CD28-CD3z CAR T cellsCD 93-CD28-CD3z CAR T cellsanti-CD93 CAR T cellsanti-CD-93 CAR T cellsanti-CD 93 CAR T cells